doi: 10.1016/s0140-6736(88)90468-0.
Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS
Affiliations
- PMID: 2901518
- DOI: 10.1016/s0140-6736(88)90468-0
Item in Clipboard
Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS
Lancet.
.
Abstract
Infusions of 55-500 ml plasma from one of two donors selected for high anti-p24 antibody titre and neutralising capacity were given to six patients with advanced AIDS. Human immunodeficiency virus (HIV) antigenaemia cleared immediately and the recipients' serum acquired the HIV antibody profile of the donor together with HIV neutralising activity. The passive antibody effects persisted for up to eleven weeks depending upon the volume of plasma given, which had a half-life of about 12 days. The infusions were followed by fewer symptoms, a transient increase in T lymphocytes, a reduction in the frequency of opportunistic infections, and a decline in the rate at which HIV could be cultured from plasma or lymphocytes.
Similar articles
-
Passive immunization in ARC and AIDS.Biotherapy. 1990;2(2):159-72. doi: 10.1007/BF02173455. Biotherapy. 1990. PMID: 2144762 No abstract available.
-
Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma.J Infect Dis. 1992 Feb;165(2):364-8. doi: 10.1093/infdis/165.2.364. J Infect Dis. 1992. PMID: 1730902 Clinical Trial.
-
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):745-50. doi: 10.1136/bmj.296.6624.745. Br Med J (Clin Res Ed). 1988. PMID: 3126959 Free PMC article.
-
[Binding of HIV-1 by "soluble" CD4 receptor--new therapeutic possibilities in AIDS].Pol Tyg Lek. 1989 Apr 24;44(17):401-2. Pol Tyg Lek. 1989. PMID: 2533976 Review. Polish. No abstract available.
-
Passive hyperimmune therapy in the treatment of AIDS and ARC.J Clin Apher. 1991;6(2):122-3. doi: 10.1002/jca.2920060215. J Clin Apher. 1991. PMID: 1938992 Review. No abstract available.
Cited by
-
Immunotherapy for infectious diseases.West J Med. 1990 Apr;152(4):401-5. West J Med. 1990. PMID: 1693458 Free PMC article.
-
Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597-601. doi: 10.1073/pnas.87.21.8597. Proc Natl Acad Sci U S A. 1990. PMID: 1700435 Free PMC article.
-
Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1411-5. doi: 10.1073/pnas.90.4.1411. Proc Natl Acad Sci U S A. 1993. PMID: 8434001 Free PMC article.
-
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10492-5. doi: 10.1073/pnas.92.23.10492. Proc Natl Acad Sci U S A. 1995. PMID: 7479826 Free PMC article.
-
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.J Virol. 1997 Oct;71(10):7198-206. doi: 10.1128/JVI.71.10.7198-7206.1997. J Virol. 1997. PMID: 9311792 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
